Loading...
12 Asia Hyperglycemics Reports
Region Covered: Asia
Study Period: 2019 - 2030
Countries Covered: Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand
Major Players: Eli Lilly and Company, Boehringer Ingelheim, Janssen, AstraZeneca, Bristol-Myers Squibb
Region Covered: Asia
Study Period: 2019 - 2030
Countries Covered: Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand
Major Players: Takeda Pharmaceuticals, Bristol-Myers Squibb, Glenmark Pharmaceuticals, Merck, Sanofi
Region Covered: Asia
Study Period: 2019 - 2030
Countries Covered: Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, Thailand, Vietnam
Major Players: Novo Nordisk, Eli Lilly and Company, Sanofi, Biocon, Gan & Lee
Region Covered: Asia
Study Period: 2019 - 2030
Countries Covered: Japan, China, South Korea, India, Australia, Malaysia, Indonesia, Philippines, Thailand
Major Players: Novo Nordisk, Glenmark Pharmaceuticals, Novartis, KISSEI PHARMACEUTICAL, Biocon
Region Covered: Asia
Study Period: 2019 - 2030
Countries Covered: United States, Canada, Germany, Spain, Italy, France, United Kingdom, Russia, Japan, China, Australia, India, South Korea, Malaysia, Indonesia, Thailand, Vietnam, Philippines, Brazil, Mexico, South Africa, Saudi Arabia, Oman, Egypt, Iran
Major Players: Glenmark Pharmaceuticals, Novartis, KISSEI PHARMACEUTICAL, Biocon, Novo Nordisk
Region Covered: Asia
Study Period: 2019 - 2030
Countries Covered: United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, Australia, South Korea, South Africa, Brazil, Argentina
Region Covered: Asia
Study Period: 2019 - 2030
Countries Covered: United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, Australia, South Korea, South Africa, Brazil, Argentina
Major Players: Abbott Laboratories, Sanofi, Mylan, Lupin, Aurobindo Pharma
Region Covered: Asia
Study Period: 2019 - 2030
Countries Covered: United States, Canada, France, Germany, Italy, Spain, United Kingdom, Russia, Mexico, Brazil, Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand, Saudi Arabia, Iran, Egypt, Oman, South Africa
Major Players: Sanofi, Novo Nordisk, Biocon, Eli Lilly and Company, Julphar
Region Covered: Asia
Study Period: 2019 - 2030
Countries Covered: United States, Canada, Germany, Spain, Italy, France, United Kingdom, Russia, Japan, China, Australia, India, South Korea, Malaysia, Indonesia, Thailand, Philippines, Vietnam, Brazil, Mexico, South Africa, Saudi Arabia, Oman, Egypt, Iran
Major Players: Novo Nordisk, Sanofi, Eli Lilly and Company, Biocon, Wockhardt
Region Covered: Asia
Study Period: 2019 - 2030
Countries Covered: United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, Australia, South Korea, South Africa, Brazil, Argentina
Major Players: Novo Nordisk, Eli Lilly and Company, Pfizer, Sanofi, Biocon
Region Covered: Asia
Study Period: 2019 - 2030
Countries Covered: United States, Canada, France, Germany, Italy, Spain, United Kingdom, Russia, Mexico, Brazil, Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand, Saudi Arabia, Iran, Egypt, Oman, South Africa
Major Players: Sanofi, Pfizer, Merck, Torrent Pharmaceuticals, Dr. Reddy’s Laboratories
Region Covered: Asia
Study Period: 2019 - 2030
Countries Covered: United States, Canada, Germany, Spain, Italy, France, United Kingdom, Russia, Japan, China, Australia, India, South Korea, Malaysia, Indonesia, Thailand, Philippines, Vietnam, Brazil, Mexico, South Africa, Saudi Arabia, Oman, Egypt, Iran
Major Players: Bristol-Myers Squibb, Glenmark Pharmaceuticals, Takeda Pharmaceuticals, Sanofi, Merck
Filter Reports
By Countries
